Ring Containing Patents (Class 514/559)
-
Publication number: 20020001615Abstract: Alfa interferon (&agr;-IFN or alpha-interferon) and liposomal all-trans retinoic acid is useful in cancer treatment with particular reference to renal cancer. Optionally, a regimen of &agr;-interferon from about 3 to about 5 million units sc daily and liposomal all-trans retinoic acid at from about 15 mg/m2 to about 90 mg/m2, or about 140 mg/m2, or about 300 mg/m2 or more. Dosage periodicity of about three times per week for both drugs in about 8 week cycles is useful.Type: ApplicationFiled: March 16, 2001Publication date: January 3, 2002Applicant: Aronex Pharmaceuticals, Inc.Inventor: David Nanus
-
Patent number: 6329425Abstract: This invention provides pharmaceutical compositions containing lipoxin compounds and therapeutic uses for the compounds in treating or preventing a disease or condition associated with columnar epithelial inflammation. The invention also discloses methods for screening for compounds useful in preventing columnar epithelial inflammation.Type: GrantFiled: October 21, 1997Date of Patent: December 11, 2001Assignee: Brigham and Women's HospitalInventors: James L. Madara, Charles N. Serhan, Sean P. Colgan
-
Patent number: 6326032Abstract: A peroxyacid antimicrobial concentrate and use composition is provided comprising a C1 to C4 peroxycarboxylic acid or a C1 to C4 peroxycarboxylic acid combined with a C6 to C18 peroxyacid in beverage processing. The combination of these materials produces a synergistic effect, providing a much more potent biocide than can be obtained by using these components separately. Other components can be added to the composition such as hydrotrope coupling agents, stabilizers, etc. An effective antimicrobial use solution is formed at low concentrations when the concentrate composition is diluted with water to a pH in the range of about 2 to 8. Sanitizing of substantially fixed, “in-place” processing lines in dairies, breweries, and other food and beverage processing operations is one utility of the composition. Another utility is in processes including aseptic cold filling of beverage containers such as cans, glass bottles or two liter PET bottles.Type: GrantFiled: November 18, 1998Date of Patent: December 4, 2001Assignee: Ecolab Inc.Inventors: Francis L. Richter, Bruce R. Cords, Michael E. Besse, Kenji Nogami
-
Patent number: 6313088Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: February 7, 1997Date of Patent: November 6, 2001Assignee: Emisphere Technologies, Inc.Inventors: Andrea Leone-Bay, Eric Wang, Donald J. Sarubbi, Harry Leipold, Nai Fang Wang
-
Patent number: 6300373Abstract: Neurotrophic and antiproliferative compounds related to the antiepileptic drug valproate are provided. These compounds are useful for promoting neuronal function as in neurodegenerative disorders and for treating neoplastic disease.Type: GrantFiled: May 22, 1995Date of Patent: October 9, 2001Assignees: American Biogenetic Sciences, Inc., University College DublinInventors: Heinz Nau, Ciaran M. Regan
-
Patent number: 6296859Abstract: Composition characterized in that it comprises, as active principle, at least one compound of formula (I): its topically acceptable salts, which R represents the characterizing chain of a saturated or unsaturated, linear or branched fatty acid containing from 3 to 30 carbon atoms, R1 represents the characterizing chain of an amino acid and m is between 1 and 5, and the constituents of at least one extract and/or of at least one tincture from plants of the Nympheacea family. The composition is useful in cosmetics.Type: GrantFiled: March 5, 1999Date of Patent: October 2, 2001Assignee: Societe d'Exploitation de Produits pour les Industries Chimiques SeppicInventor: Corinne Stoltz
-
Publication number: 20010009920Abstract: Pharmaceutical combination compositions including certain estrogen agonists/antagonists and prostaglandins or prostaglandin agonists/antagonists. The compositions are useful for the treatment of bone disorders including osteoporosis.Type: ApplicationFiled: December 13, 2000Publication date: July 26, 2001Inventors: Hua Zhu Ke, David D. Thompson
-
Patent number: 6262038Abstract: A germicidal composition suitable for cleaning fruits, vegetables, skin and hair, includes a mixture of fruit acids and a surfactant. The surfactant may be an anionic surfactant (such as sodium lauryl sulfate), a sophorose lipid biosurfactant, or a combination of the two surfactants. The mixture of fruit acids may include citric acid, glycollic acid, lactic acid, malic acid and tartaric acid. The fruit acids are preferably present, in an aqueous solution, in a sufficient amount to produce a pH of about 2-6, for example 3.8-4.2. The compositions of the present invention are germicidal, and are sufficient to kill 100% of E. coli, Salmonella and Shigelia in 30 seconds after application to the surface of the object.Type: GrantFiled: April 16, 1999Date of Patent: July 17, 2001Assignee: David Christal, Ltd.Inventors: Deborah Pierce, Timothy J. Heilman
-
Patent number: 6262118Abstract: The present invention provides the use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes and hyperlipidemia.Type: GrantFiled: June 4, 1999Date of Patent: July 17, 2001Assignee: MetaBolex, Inc.Inventors: Kenneth L. Luskey, Jian Luo
-
Patent number: 6258846Abstract: The present disclosure relates to novel nutritional compositions containing linoleic acid and/or linolenic acid which optimize child neurological development and provide improved nutritional support for women prior to and during lactation. The nutritional compositions are intended for use by women to optimize infant neurological development and provide improved nutritional support for women prior to, during and after lactation.Type: GrantFiled: June 1, 1999Date of Patent: July 10, 2001Assignee: Drugtech CorporationInventors: Marc S. Hermelin, R. Saul Levinson, George Paradissis
-
Patent number: 6255496Abstract: Selective inhibitors of the cPLA2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases.Type: GrantFiled: April 27, 1999Date of Patent: July 3, 2001Assignee: Bristol-Myers Squibb CompanyInventors: Jacques Banville, Yonghua Gai, Graham Johnson, Fred Christopher Zusi, James R. Burke
-
Patent number: 6251941Abstract: Administration of retinoids by inhalation is used to overcome the chronic toxicity problems presented by systemic administration and to make retinoid therapy available as an option for the prevention of epithelial cancers of the respiratory tract, especially those that are associated with tobacco use. Retinoids are administered by inhalation to the respiratory tract of the individual as an air-borne composition with a metered dose aerosol-producing inhaler, in which the retinoid is dissolved in a combination of a pharmaceutically acceptable chlorofluorocarbon propellant and an alkylamine solubilizing agent.Type: GrantFiled: December 29, 1998Date of Patent: June 26, 2001Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: William P. Tong, Raymond P. Warrell
-
Patent number: 6228383Abstract: Use of fatty acid esters as bioadhesive substances. The fatty acid esters have molecular weights below about 1000 dalton and the fatty acid component of the fatty acid ester is a saturated or unsaturated fatty acid having a total number of carbon atoms of from C8 to C22. Particularly suitable fatty acid esters for use according to the invention are fatty acid esters which are selected from the group consisting of fatty acid esters of polyhydric alcohols, fatty acid esters of hydroxycarboxylic acids, fatty acid esters of monosaccharides, fatty acid esters of glycerylphosphate derivatives, fatty acid esters of glycerylsulfate derivative, and mixtures thereof. Excellent bioadhesive properties have been observed for fatty acid esters are glyceryl monooleate, glyceryl monolinoleate or glyceryl monolinolenate.Type: GrantFiled: June 5, 1995Date of Patent: May 8, 2001Assignee: GS Development abInventors: Jens Hansen, Lise Sylvest Nielsen, Tomas Norling
-
Patent number: 6211213Abstract: Stable microbicidal compositions containing a 3-isothiazolone compound, organic oxidants, copper salts and water are disclosed. Also disclosed are methods of stabilizing 3-isothiazolone compositions.Type: GrantFiled: April 12, 2000Date of Patent: April 3, 2001Assignee: Rohm and Haas CompanyInventor: Beverly Jean El A'mma
-
Patent number: 6197801Abstract: An injectable pharmaceutical composition for treatment of erectile dysfunction. The composition includes prostaglandin E-1, and optionally further includes levsin and/or additional vasodilators such as diltiazem HCl, verapamil, chlorpromazine, d,L-hyoscyamine, and 6,7-dimethoxy-1-veratrylisoquinoline HCl. The composition is effective for long-term restoration of normal erectile function to a patient having erectile dysfunction. The ability to reverse erectile dysfunction may be further enhanced by the inclusion of vitamin B-6, B-12, folic acid, and/or TPA. Also disclosed are methods for treatment and reversal of erectile dysfunction by injecting the pharmaceutical composition into the penis, either by subcutaneous or intracavernosal injection.Type: GrantFiled: May 28, 1999Date of Patent: March 6, 2001Assignee: USA Doctors Products, Inc.Inventor: An-Hao Lin
-
Patent number: 6187818Abstract: This invention comprises new formulations and methods of preparing a new formulations of prostaglandins and in particular dinoprost tromethamine, where the pH of the formulation is adjusted to between about 5.5-7.5 and where the the concentration of benzyl alcohol is between about 1.2 to 2.0 mg/ml.Type: GrantFiled: June 17, 1998Date of Patent: February 13, 2001Assignee: Pharmacia & Upjohn CompanyInventor: Robert G. Re
-
Patent number: 6180669Abstract: A compound effect for the treatment of dermatological disorders comprises a mono- or diester of an &agr;,&ohgr;-dicarboxylic acid, wherein the alcohol moiety of the said ester comprises a keratolytically active alcohol. The compound may have the formula, where n is in the range of 6 to 12; m is in the range of 0 to 8; R′ is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl, OH, NHR″, CONHR″ and COOR″; R″ is selected from the group consisting of alkyl, aryl, alkenyl, and benzyl; and Y is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl and X.Type: GrantFiled: April 5, 1999Date of Patent: January 30, 2001Assignee: Tamarkin Pharmaceutical Innovation Ltd.Inventor: Dov Tamarkin
-
Patent number: 6177470Abstract: Optimum conditions for prostaglandin synthesis are provided by internally administering an ascorbic-6-acid ester of gamma-linolenic acid or an ascorbic-6-acid ester of dihomo-gamma-linolenic acid.Type: GrantFiled: March 2, 1998Date of Patent: January 23, 2001Assignee: Scotia Holdings PLCInventors: David F Horrobin, Philip Knowles, Mehar S Manku
-
Patent number: 6177468Abstract: This invention provides pharmaceutical compositions containing lipoxin compounds and therapeutic uses for the compounds in treating or preventing a disease or condition associated with columnar epithelial inflammation. The invention also discloses methods for screening for compounds useful in preventing columnar epithelial inflammation.Type: GrantFiled: February 2, 2000Date of Patent: January 23, 2001Assignee: The Brigham and Women's Hospital, Inc.Inventors: James L. Madara, Charles N. Serhan, Sean P. Colgan
-
Patent number: 6172112Abstract: The present invention provides new retinoid compounds and uses of the compounds in humans and animals for chemoprevention of skin and/or breast cancer and for therapy of leukemia.Type: GrantFiled: April 6, 1999Date of Patent: January 9, 2001Assignee: UAB Research FoundationInventors: Wayne J. Brouillette, Donald D. Muccio
-
Patent number: 6150411Abstract: Dyslexia or inadequate night vision is treated by administering effective amounts of docosohexaenoic acid optionally in association wit other n-3 essential fatty acids and n-6 essential fatty acids.Type: GrantFiled: February 28, 1997Date of Patent: November 21, 2000Inventor: Barbara Jacqueline Stordy
-
Patent number: 6136865Abstract: A method for reduction of the viral infectiousness of potentially infectious material, such as human or animal body fluids or fractions derived therefrom from which biologically active substances can be isolated, wherein the infectiousness is due to non-lipid-coated viruses characterized in thatsaid potentially infectious material for the isolation of said biologically active substances is treated witha hydrophobic phase which is essentially insoluble in water and is capable of forming a two-phase system with said potentially infectious material, andsaid hydrophobic phase is separated from the potentially infectious material thus treated.Type: GrantFiled: June 7, 1995Date of Patent: October 24, 2000Assignee: Octapharma AGInventors: Lothar Biesert, Horst Schwinn, Wolfgang Marguerre
-
Patent number: 6121320Abstract: A method of treating leukemia which includes administering an effective amount of composition comprising suramin and a biological response modifier, wherein the suramin and the biological response modifier show synergistic or additive anti-leukemic activity. A pharmaceutical composition is also disclosed.Type: GrantFiled: February 26, 1998Date of Patent: September 19, 2000Assignee: The University of Kentucky Research FoundationInventor: Michael A. Doukas
-
Patent number: 6071962Abstract: Disclosed the use of compounds of Formula (I) depicted below, as active principals for treating skin conditions, compositions containing these compounds, and methods of treating skin conditions using these compounds and compositions. ##STR1## where R.sub.4 is (CR.sub.5 R.sub.6 --CR.sub.7 R.sub.8 --X.sub.1).sub.n --CR.sub.9 R.sub.10 R.sub.11 ; n is an integer from 1 to 18; R.sub.1, R.sub.2, R.sub.3, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11 are, independently, hydrogen or non-hydrogen substituents comprising alkyls, alkenyls, oxa-alkyls, aralkyls and aryls; and X, X.sub.1, Y and Z are, independently, oxygen, amine or sulfur, with preferred compounds being those in which X, X.sub.1, Y and Z are oxygen, and R.sub.1, R.sub.2, R.sub.3, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11 are hydrogen.Type: GrantFiled: September 14, 1998Date of Patent: June 6, 2000Assignee: Avon Products, Inc.Inventors: Dmitri Ptchelintsev, Neil D. Scancarella, Robert Kalafsky
-
Patent number: 6069169Abstract: The present invention is directed to the use of compounds of Formula (I), depicted below, as active principals for treating skin conditions; compositions containing these compounds; and methods of treating skin conditions using these compounds and compositions. ##STR1## wherein R.sub.4 is (CR.sub.5 R.sub.6 --CR.sub.7 R.sub.8 --X.sub.1).sub.n --CR.sub.9 R.sub.10 R.sub.11, n is an integer from 1 to 18; R.sub.1, R.sub.2, R.sub.3, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11, are independently, hydrogen or non-hydrogen substituents; and X, X.sub.1, Y and Z are independently, 0, NH, or S.Type: GrantFiled: June 2, 1997Date of Patent: May 30, 2000Assignee: Avon Products, Inc.Inventors: Dmitri Ptchelintsev, Neil Scancarella, Robert Kalafsky
-
Patent number: 6066669Abstract: A nutritional formulation containing bacterial amounts of diacetyltartaric acid esters of mono- and diglycerides is provided. A process of inhibiting bacterial infections including the step of feeding the nutritional composition to a subject is also provided.Type: GrantFiled: April 16, 1999Date of Patent: May 23, 2000Assignee: Abbott LaboratoriesInventors: Steven N. Anderson, Milo Duane Hilty, Terry Bruce Mazer, Joseph Schaller, Melinda Guzman-Harty, Theresa Siu-Ling Wai Lee, Lisa Ann Reaves, Jin-Zhou Liu
-
Patent number: 6060513Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: February 7, 1997Date of Patent: May 9, 2000Assignee: Emisphere Technologies, Inc.Inventors: Andrea Leone-Bay, Eric Wang, Donald J. Sarubbi, Harry R. Leipold
-
Patent number: 6054139Abstract: The invention relates to a cleaning and/or disinfecting composition comprising a tertiary alkyl amine and an alkyl betaine.Type: GrantFiled: May 9, 1997Date of Patent: April 25, 2000Assignee: Diversey Lever Inc.Inventors: Ronald Joseph Lambert, Moira Diane Johnston, Eduard C. van Baggem, Gijsbertus de Goederen
-
Patent number: 6034131Abstract: A diphenyl ether of the formula I, ##STR1## or a salt or N-oxide thereof wherein Q is C(CO.sub.2 CH.sub.3).dbd.CHCH.sub.3, C(CONH.sub.2).dbd.CHOCH.sub.3, C(CO.sub.2 CH.sub.3).dbd.NOCH.sub.3, C(CONHCH.sub.3).dbd.NOCH.sub.3 or N(OCH.sub.3)--CO.sub.2 CH.sub.3 ;n is 0 or 1;R.sup.1 is hydrogen or a carbon bonded organic radical;R.sup.2 is hydrogen or an organic radical bonded via C, O, S or N;x is 0, 1 or 2;R.sup.3 is cyano, nitro, halogen or an organic radical bonded via C, O, S or N; ory is 0, 1, 2 or 3;R.sup.4 is cyano, halogen, alkyl, haloalkyl or alkoxy,intermediates and processes for its preparation, and its use.Type: GrantFiled: September 3, 1998Date of Patent: March 7, 2000Assignee: BASF AktiengesellschaftInventors: Klaus Oberdorf, Wassilios Grammenos, Hubert Sauter, Thomas Grote, Bernd Muller, Reinhard Kirstgen, Herbert Bayer, Arne Ptock, Michael Rack, Albrecht Harreus, Franz Rohl, Eberhard Ammermann, Volker Harries, Gisela Lorenz, Siegfried Strathmann
-
Patent number: 6025511Abstract: A method of inhibiting parasitic activity is disclosed in which the biosynthesis, structure and/or function of the glycosyl phosphatidylinositol (GPI) anchor of said parasite may be affected by incorporating into said GPI anchor selected analogs of myristic acid containing various heteroatoms, substituents and unsaturated bonds, including ester-containing analogs, ketocarbonyl-containing analogs, sulfur-containing analogs, double bond- and triple bond-containing analogs, aromatic moiety-containing analogs, nitrated analogs and halogenated analogs.Type: GrantFiled: March 31, 1998Date of Patent: February 15, 2000Assignees: Washington University, Johns Hopkins UniversityInventors: Jeffrey I. Gordon, George W. Gokel, Paul T. Englund
-
Patent number: 6024986Abstract: The direct introduction or injection of peroxy compounds into a transpiration layer in a plant structure found inside the protective layer, bark or husk of a growing plant is described as an effective method in treating plant disease and can achieve levels of protection unavailable in the simple application of the materials to the leaf, stem, root or plant environment including air or soil.Type: GrantFiled: May 24, 1999Date of Patent: February 15, 2000Assignee: Ecolab Inc.Inventor: Robert D.P. Hei
-
Patent number: 6004987Abstract: The present invention relates to the use of at least one ligand which is specific for RXR receptors, in the preparation of a pharmaceutical composition to be administered systemically and intended to increase the cellular proliferation and/or differentiation modulatory activity of a ligand for at least one receptor of the superfamily of steroidal/thyroidal receptors, other than a ligand which is specific for the RXR receptors, and which can heterodimerize with the RXRs, which is applied topically.Type: GrantFiled: June 19, 1996Date of Patent: December 21, 1999Assignee: Centre International de Recherches Dermatologiques GaldermaInventors: Michel Demarchez, Andre Jomard
-
Patent number: 6001874Abstract: A non-toxic arthropod control composition is disclosed for application to foliage for plant protection. The composition includes behavior interfering compounds, agricultural oil and/or surface active compounds and diluents. The behavior interfering compounds may be any known conventional compound capable of interrupting or altering the normal behavioral sequences of the target. The agricultural oil can be a vegetable oil.Type: GrantFiled: June 20, 1997Date of Patent: December 14, 1999Inventor: Dan Veierov
-
Patent number: 5998642Abstract: A method of inhibiting parasitic activity is disclosed in which the biosynthesis, structure and/or function of the glycosyl phosphatidylinositol (GPI) anchor of said parasite may be affected by incorporating into said GPI anchor selected analogs of myristic acid containing various heteroatoms, substituents and unsaturated bonds, including ester-containing analogs, ketocarbonyl-containing analogs, sulfur-containing analogs, double bond- and triple bond-containing analogs, aromatic moiety-containing analogs, nitrated analogs and halogenated analogs.Type: GrantFiled: December 15, 1997Date of Patent: December 7, 1999Assignee: Washington UniversityInventors: Jeffrey I. Gordon, George W. Gokel, Paul T. Englund
-
Patent number: 5998395Abstract: Inflammatory dermatoses are controlled and cleared by topical application to the affected areas of the skin of a composition containing both a corticosteroid and a retinoid. The combined therapy is more effective than either active ingredient alone and is particularly effective for chronic dermatoses which are or have become resistant to corticosteroid treatment alone. After clearing has been obtained with once or twice daily applications of the corticosteroid-retinoid composition, usually after several weeks, clearance can be maintained by less frequent application or lower concentrations of the composition or by application of only one of the corticosteroid or retinoid, less potent corticosteroids, or other non-steroidal therapies, depending upon the particular dermatosis being treated.Type: GrantFiled: September 10, 1993Date of Patent: December 7, 1999Inventor: Albert M. Kligman
-
Patent number: 5990166Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: February 7, 1997Date of Patent: November 23, 1999Assignee: Emisphere Technologies, Inc.Inventors: Andrea Leone-Bay, Eric Wang, Donald J. Sarubbi, Harry Leipold
-
Patent number: 5968982Abstract: Pharmaceutical agents for treating diabetus mellitus which contain a compound of formula I ##STR1## as the active substance, in which A, B, A' and W have the meanings stated in the claims, new compounds of formula I as well as processes for their production.Type: GrantFiled: July 8, 1997Date of Patent: October 19, 1999Assignee: Roche Diagnostics GmbHInventors: Edgar Voss, Johannes Pill, Peter Freund
-
Patent number: 5968989Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.Type: GrantFiled: June 7, 1995Date of Patent: October 19, 1999Assignees: The Salk Institute for Biological Studies, Baylor College of Medicine, Ligand Pharmaceuticals, Inc.Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
-
Patent number: 5955502Abstract: Use of fatty acid esters as bioadhesive substances. The fatty acid esters have molecular weights below about 1000 dalton and the fatty acid component of the fatty acid ester is a saturated or unsaturated fatty acid having a total number of carbon atoms of from C.sub.8 to C.sub.22. Particularly suitable fatty acid esters for use according to the invention are fatty acid esters which are selected from the group consisting of fatty acid esters of polyhydric alcohols, fatty acid esters of hydroxycarboxylic acids, fatty acid esters of monosaccharides, fatty acid esters of glycerylphosphate derivatives, fatty acid esters of glycerylsulfate derivative, and mixtures thereof. Excellent bioadhesive properties have been observed for fatty acid esters are glyceryl monooleate, glyceryl monolinoleate or glyceryl monolinolenate.Type: GrantFiled: March 27, 1997Date of Patent: September 21, 1999Assignee: GS Development ABInventors: Jens Hansen, Lise Sylvest Nielsen, Tomas Norling
-
Patent number: 5952384Abstract: A method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response is disclosed. Mammalian cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Composition, for reducing and treating undesired inflammatory response are also disclosed.Type: GrantFiled: March 18, 1998Date of Patent: September 14, 1999Assignee: Cellular Sciences, Inc.Inventor: Stanley E. Katz
-
Patent number: 5932613Abstract: A method of treating cancer with a pharmaceutical composition containing a pine root (Deutero Mycetes) fungal metabolite or an analog or derivative thereof.Type: GrantFiled: July 3, 1996Date of Patent: August 3, 1999Assignee: Millennium Pharmaceuticals, Inc.Inventors: Wei-Dong Jiang, Zhi-Dong Jiang, Rex T. Gallagher
-
Patent number: 5932195Abstract: Arylaminomethylenecamphor derivatives of the formula (1) ##STR1## where the C.dbd.C double bond is in the Z or E configuration, and the variables have the following meanings:R.sup.1 H, CH.sub.3,R.sup.2 H, C.sub.1 -C.sub.6 -alkyl, C.sub.3 -C.sub.8 -cycloalkyl, C.sub.2 -C.sub.6 -alkenyl, C.sub.3 -C.sub.8 -cycloalkenyl, aryl or substituted aryl,R.sup.3 H, C.sub.1 -C.sub.6 -alkyl, C.sub.3 -C.sub.8 -cycloalkyl, aryl, substituted aryl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.8 -acyl,Ar aryl, substituted aryl, hetaryl or substituted hetaryl,are used as sunscreen agents, especially in cosmetic and pharmaceutical formulations.Type: GrantFiled: January 13, 1998Date of Patent: August 3, 1999Assignee: BASF AktiengesellschaftInventors: Michael Drogemuller, Volker Bomm, Volker Schehlmann, Horst Westenfelder
-
Patent number: 5929057Abstract: 9-Cis-retinoic acid-.alpha.-tocopherol esters, pharmaceutical compositions containing the same and use of the same as a medicine for the treatment of leukemia, in particular, the remission of leukemia are provided and a combined use of a 9-cis-retinoic acid-.alpha.-tocopherol ester and either 1.alpha.,25-dihydroxyvitamin D.sub.3 or 9-cis-retinoic acid exhibits a synergistic effect in the treatment of leukemia without any side effects caused by 1.alpha.,25-dihydroxyvitamin D.sub.3 or 9-cis-retinoic acid.Type: GrantFiled: June 5, 1998Date of Patent: July 27, 1999Assignee: Nisshin Flour Milling Co., Ltd.Inventors: Makoto Makishima, Yasuhiro Kanatani, Yoshio Honma, Kohei Inomata, Takao Kishiye
-
Patent number: 5908862Abstract: A process of treating a bacterial infection in a subject in need of such treatment including the step of administering to the subject an effective bactericidal amount of diacetyltartaric acid esters of mono- and diglycerides is provided. Pharmaceutical compositions containing diacetyltartaric acid esters of mono- and diglycerides as an active bactericidal agent are also provided.Type: GrantFiled: July 31, 1996Date of Patent: June 1, 1999Assignee: Abbot LaboratoriesInventors: Theresa Siu-Ling Wai Lee, Joseph Schaller, Steven N. Anderson, Terry Bruce Mazer, Milo Duane Hilty, Melinda Guzman-Harty, Jonathan Allan Meulbroek, Patricia Joan Ewing, Jin-Zhou Liu
-
Patent number: 5869067Abstract: The present invention relates to new aromatic compounds, to their preparation and to their use in human and veterinary medicine and in cosmetic compositions.Type: GrantFiled: September 26, 1994Date of Patent: February 9, 1999Assignee: Centre International De Recherches Dermatologiques Galderma (CIRD Galderma)Inventors: Jean-Phillippe Rocher, Jean-Michel Bernardon
-
Patent number: 5869529Abstract: The invention provides a topical pharmaceutical composition for the prevention and treatment of lesions and sores of the skin or mucosa associated with a herpes virus, comprising a salt of an unsaturated C.sub.14-18 fatty acid having 1-2 double bonds as active ingredient therein, in combination with a pharmaceutically or cosmetically acceptable carrier.Type: GrantFiled: February 6, 1996Date of Patent: February 9, 1999Assignee: Agis Industries (1983) Ltd.Inventors: Amnon Sintov, Rina Uzan
-
Patent number: 5863944Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: April 30, 1997Date of Patent: January 26, 1999Assignee: Emisphere Technologies, Inc.Inventors: Andrea Leone-Bay, David Gschneidner, Eric Wang, Donald J. Sarubbi
-
Patent number: 5861431Abstract: The present invention provides a method of treating incontinence in a patient that has a bladder and a urethra. The urethra forms a lumen for draining the bladder. The method comprises the steps of delivering an agent into the lumen and passing the agent from the lumen to internal body tissue. The agent increases restriction of the lumen thereby providing increased control over urine flow from the bladder.Type: GrantFiled: June 7, 1995Date of Patent: January 19, 1999Assignee: Iotek, Inc.Inventors: Keith R. Hildebrand, Jan Ellen O. Fowler, Dezso K. Levius
-
Patent number: 5847003Abstract: Described are the use of compounds of Formula (I) depicted below, as active principals for treating skin conditions and compositions containing these compounds, ##STR1## where R.sub.4 is (CR.sub.5 R.sub.6 --CR.sub.7 R.sub.8 --X.sub.1).sub.n --CR.sub.9 R.sub.10 R.sub.11 ; n is an integer from 1 to 18; R.sub.1, R.sub.2, R.sub.3, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11 are, independently, hydrogen or substituents selected from alkyls, alkenyls, oxa-alkyls, aralkyls and aryls; and X, X.sub.1, Y and Z are, independently, oxygen.Type: GrantFiled: June 4, 1996Date of Patent: December 8, 1998Assignee: Avon Products, Inc.Inventors: Dmitri Ptchelintsev, Neil Scancarella, Robert Kalafsky
-
Patent number: RE36068Abstract: Various effects of photoaging or sundamage of skin including impairment of differentiation of epidermal epithelial cells and loss of collagen fibers, abnormal changes in elastic fibers and deterioration of small blood vessels in the dermis of the skin are retarded by applying topically to the epidermis in a maintenance therapy program effective amounts of retinoids including retinoid derivatives and stereoisomers thereof such that epithelial growths are substantially reduced and prevented and the skin substantially regains and maintains its firmness, turgor and elasticity. Moreover, with persistent treatment dermal blood cells and vessels increase and the epidermis and dermis thicken, resulting in improved ability of the skin to sense, resist and recover from irritation or injury. Further, hyperpigmentation, lines and wrinkles due to aging are reduced and prevented. The treatment is particularly useful for human facial skin and preferably applied in amounts insufficient to cause excessive irritation.Type: GrantFiled: April 2, 1996Date of Patent: January 26, 1999Inventor: Albert M. Kligman